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Abstract
Background: There are few data regarding HCV treatment initiation among HIV/HCV coinfected patients. The
objective of this study was to analyze the changing patterns of HCV coinfection and HCV treatment initiation over
time in a large French cohort of HIV/HCV coinfected patients at the beginning of DAA’s era and to analyze factors
associated with treatment initiation.
Methods: All HIV/HCV coinfected patients enrolled during 2000–2012 were analyzed. HCV status was defined per
calendar year as naïve, spontaneous cure, sustained virological response (SVR), failure or reinfection. HCV treatment
initiation rate was determined per year. Trends over time were analyzed using Chi-2 test for trend and linear
regression analysis. The effect of covariates on treatment initiation over time was analyzed using generalized
estimating equations.
Results: Among 34,308 HIV-infected patients enrolled between 2000 and 2012, 5,562 were HCV coinfected. HCV
prevalence declined from 38.4 to 15.1 %. HCV treatment initiation rate fluctuated from 5.6 to 7.4 %/year from 2000 to
2007, dropped to 5.6 % in 2011 and increased to 8.5 % in 2012 due to the use of first-generation DAAs (29.1 % of
initiations in 2012). Cumulative HCV treatment initiation rate increased from 14.8 % in 2000 to 54.7 % in 2012. HCV cure
rate increased from 12.4 to 45.2 %. Older age, male gender, male homosexuality, high CD4, undetectable HIV-RNA, CDC
stage A-B, and severe fibrosis/cirrhosis were associated with a higher treatment initiation rate. The role of HCV
genotype 1, CDC stage, fibrosis and recent HCV infection on treatment initiation rate changed over time.
Conclusion: A high rate of HCV treatment initiation was observed at the beginning of DAAs era in HIV/HCV coinfected
patients. Given the very high efficacy of new DAA-based regimens and if treatment initiation keeps increasing, HCV
prevalence among HIV patients will drastically decrease during the forthcoming years.
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Background
Because of shared routes of transmission, hepatitis C virus
(HCV) infection is frequent among HIV patients [1] with
geographical variations [1–3]. In France, about 16-18 % of
HIV patients were HCV coinfected in 2010–2011 [4].
Since liver fibrosis is known to progress faster in HIV/
HCV coinfected patients compared to HCV monoinfected
ones [5, 6], HCV coinfection is associated with a higher
morbidity and mortality [7]. After the introduction of
combined antiretroviral therapy (cART), liver disease has
become the leading cause of death in HIV-positive pa-
tients [8–10] suggesting to early initiate HCV treatment
in these patients. However, the poor virological results
and tolerability of the standard Peg-interferon (PEG-
IFN)/ribavirin combination may have slowed down
treatment uptake in a population which was considered
difficult to treat [11].
Among HIV patients, HCV treatment uptake from 5
to 40 % have been reported worldwide [12–19]. A con-
trolled HIV infection, good compliance to follow-up,
being off-drugs, low fibrosis, male gender and HIV-risk
factors other than IVDU were reported as predictors of
HCV treatment [12–15, 17, 18].
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The development of direct acting antiviral agents
(DAAs) introduced a new era in HCV treatment with
very high sustained virological response (SVR) rates
whatever the patient profile and the viral genotype [20].
Similar results have been observed in HIV/HCV coin-
fected patients leading current international guidelines
to consider HCV treatment in this population using
the same treatment regimens as in monoinfected ones
[21, 22]. Considering the better tolerability and spec-
tacular results of these new treatments, one could ex-
pect a rapid increase in treatment uptake and cure rate
in both populations.
The objective of this study was to analyze the changing
patterns of HCV coinfection and HCV treatment initi-
ation over time in a large French cohort of HIV/HCV
coinfected patients at the beginning of DAA’s era and to
analyze factors associated with treatment initiation.
Methods
Patients
Patients’ information was collected from the Dat’AIDS
cohort, a collaborative network of French HIV treatment
centers [23]. All HIV/HCV coinfected patients enrolled
in the cohort between 2000 and 2012 were included.
Demographic, biological and virological data were col-
lected from NADIS® (Fedialis Medica, Marly le Roi,
France), a standardized electronic medical record in
which all patients’ data are recorded with no time delay
in a structured database, allowing use of the database for
epidemiological studies [23]. HCV infection was defined
as a positive HCV serology, and/or a detectable HCV-
RNA in serum. Each patient with at least one visit dur-
ing the period was enrolled in the study. Thus, the num-
ber of patients followed up each year varies over time
depending on new inclusions in the cohort, lost to
follow-up or deaths. The status of each patient was de-
fined at the beginning of each calendar year as naive
(never treated for HCV), spontaneous cure (confirmed
negative HCV-RNA in a patient with positive HCV anti-
bodies in the absence of a specific treatment), SVR
(negative HCV-RNA more than 6 months following
treatment), treatment failure (positive HCV-RNA at the
end of treatment or less than 6 months after the end of
treatment, regardless of treatment duration), reinfection
(positive HCV-RNA more than 6 months following the
end of a successful treatment or following a spontaneous
cure, or HCV infection with a different genotype (sub-
types excluded), regardless of the time period). HCV
treatment included standard interferon and PEG-IFN
with or without ribavirin and the first-generation DAAs
for the more recent years (telaprevir and boceprevir).
Ribavirin alone and long-term interferon for anti-
fibrosing effect were not considered as an eradication
strategy. Treatment periods with interruptions of less
than 3 months were considered as the same line of treat-
ment, as well as initiation of a new treatment within
3 months of a previous one. Patients receiving treatment
across 2 calendar years were considered as on-treatment
the first year, while their final response was defined the
following year. Thus, the status of each patient was only
defined once for each calendar year. Virological response
was assessed until July 2013 for patients with treatment
initiation in 2012. Retreatment for a given year con-
cerned all patients who had been treated any time before
this given year.
Fibrosis was assessed through liver biopsy, transient
elastography (FibroScan®, EchoSens, Paris, France), or
FibroTest® (BioPredictive, Paris, France). If two or more
evaluations were performed a given year, only one as-
sessment was considered according to the following
hierarchical classification: liver biopsy > FibroScan® >
FibroTest®. Fibrosis was scored using the METAVIR
scoring system [24].
Statistical analysis
Qualitative variables are presented as numbers and per-
centages whereas quantitative variables are presented
with the median and interquartile range (IQR). Trends
over time were analyzed using Chi-2 test for trend and
linear regression analysis.
Treatment initiation rate was determined per calendar
year, either in the population of patients with a detect-
able HCV-RNA, or for the naive and the failing sub-
populations. The cumulative treatment initiation rate
was determined as the percentage of patients followed a
given year who had been previously treated or who
started treatment this year. The cure rate was deter-
mined as the percentage of patients with SVR among all
treated patients at that time. Longitudinal analysis of
HCV treatment initiation rate was performed using gen-
eralized estimating equations (GEE) [25]. This approach
allowed us to make inferences at the population level,
taking into account the possible within-patient correl-
ation (i.e., non-independence) of treatment initiation
over time and to study the influence of covariables on
treatment initiation [26]. For each covariable, two types
of effects were tested in a multivariate model including
the time variable, the covariable and the interaction of
the covariable with time. The p-value associated with
the covariable effect indicated whether the probability of
treatment initiation differed between different levels of
the covariable. The p-value associated with the inter-
action effect indicated whether different evolution of
treatment initiation existed according to the levels of the
covariable. P-values below 0.05 were considered statisti-
cally significant. All analyses were performed using IBM
SPSS Statistics for Windows, Version 19.0 (IBM Corp.,
Armonk, NY, USA) and R [27] for the GEE analysis.
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Results
Patients’ characteristics
Among 34,308 HIV-infected patients enrolled between
2000 and 2012 in the Dat’AIDS cohort, 5,562 (16.2 %)
were coinfected with HCV. Patients’ characteristics at
entry in the cohort are presented in Table 1. Coin-
fected patients were mostly male (72 %) with a median
age of 39 years.
Epidemiological characteristics of HIV/HCV coinfected
patients over time
HCV prevalence declined from 38.4 % in 2000 to 15.1 %
in 2012 (p < 0.0001). Sex ratio slightly increased from
2.27 to 2.54 during the period (p < 0.0001).
The proportion of IVDU decreased regularly from
75.0 % in 2000 to 61.6 % in 2012. In parallel, presumed
sexual transmission increased from 6.4 to 13.0 %.
During the study period, 748 patients died, represent-
ing an overall mortality rate of 13.4 %. Among these pa-
tients, 21.8 % died from either cirrhosis complications
(17.9 %) or hepatocellular carcinoma (3.9 %) whereas
other causes of death included AIDS or AIDS-related
cancer (14.6 %), cardiovascular disease (7.9 %), other
cancer (7.9 %), and suicide (3.3 %). The death rate fluc-
tuated from 0.6 % in 2000 to 1.2 % in 2012 but without
significant time trend.
The most frequent genotype was genotype 1 (53.4 %)
followed by genotype 3 (24.3 %) and 4 (18.6 %). The geno-
type distribution remained almost constant over time.
HIV characteristics
Twenty-nine percent of the patients had an AIDS diag-
nosis (CDC stage C). The proportion of patients receiv-
ing antiretroviral treatment increased from 74.6 % in
2000 to 90.7 % in 2012 (p < 00001). During the same
period, the median CD4 cell count increased from 376/
mm3 to 561/mm3 (p < 0.0001) and the proportion of pa-
tients with an HIV-RNA <200 copies/mL under cART
increased from 33.7 to 95.8 % (p < 0.0001) (Additional
file 1: Figure S1).
Fibrosis evaluation
Fibrosis evaluation per calendar year increased during
the study period from 8.7 to 25.0 % (p < 0.0001), notably
in naive patients (from 6.9 to 24.2 %) and in patients
with a previous virological failure (from 17.7 to 37.7 %).
If a two-year period was considered, the rate of fibrosis
evaluation in 2011–2012 reached 31.7 % in naive pa-
tients and 52.8 % in failing patients.
Non-invasive techniques progressively replaced liver
biopsy during the period (Additional file 2: Figure S2).
The proportion of patients with documented cirrhosis
(F4) or severe fibrosis (F3) increased from 18.4 % in
2000 to 40.8 % in 2004, then declined to 24.5 % in 2010
and remained stable thereafter (Additional file 3: Figure
S3). In 2012, fibrosis stage was F0-1 in 45.5 % of pa-
tients, F2 in 27.1 %, F3 in 8.8 % and F4 in 18.7 %.
HCV treatment initiation rate
Among all patients with detectable HCV-RNA, HCV
treatment initiation rate increased from 5.6 to 7.4 % per
year from 2000 to 2007, dropped to 5.6 % in 2011 and
increased again to 8.5 % in 2012 (Fig. 1a). Between 2010
Table 1 Patients’ characteristics (n = 5,562)
Characteristic
Male, n (%) 3976 (71.5 %)
Age (year), median (IQR) 39 (35–43)
HIV risk factor, n (%)
Intravenous drug use 3330 (59.9 %)
Hemophilia, transfusion, nosocomial 310 (5.6 %)
Heterosexual contact 990 (17.8 %)
Men having sex with men 731 (13.1 %)
Other, unknown 201 (3.6 %)
Known duration of HIV infection (year), median (IQR) 11 (5–14)
CDC stage, n (%)
Stage A 2731 (49.1 %)
Stage B 1204 (21.6 %)
Stage C 1626 (29.2 %)
Under cART at entry, n (%) 3554 (63.9 %)
Under cART during follow up, n (%) 1648 (29.6 %)
cART naive, n (%) 360 (6.5 %)
Deceased 748 (13.4 %)
Known duration of HCV infection (year), median (IQR) 2 (0–7)
HCV risk factor, n (%)
Intravenous drug use 3588 (64.5 %)
Hemophilia, transfusion, nosocomial 339 (6.1 %)
Sexual 580 (10.4 %)
Other, unknown 1055 (19.0 %)
HCV genotype information available
All cohort 3137 (56.4 %)
Patient not spontaneously cured 3086 (59.4 %)
HCV genotype
Genotype 1 1676 (53.4 %)
Genotype 2 99 (3.2 %)
Genotype 3 763 (24.3 %)
Genotype 4 584 (18.6 %)
Genotype 5 4 (0.1 %)
Genotype 6 4 (0.1 %)
Fibrosis evaluation, n (%) 2869 (51.6 %)
cART combination antiretroviral therapy, CDC Centers for Disease Control and
Prevention, HCV hepatitis C virus, HIV human immunodeficiency virus, IQR
interquartile range, SVR sustained virological response
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and 2012, 70 patients were treated with DAA among
whom 33 % were naive and 67 % were previous non-
responders. From 2010 to 2012, treatment initiations
with first-generation DAAs increased from 0.1 to 2.5 %
and represented 29.1 % of all treatment initiations in
2012. First treatment initiation rate dropped to 3.0 % in
2011 and increased to 4.2 % in 2012 whereas retreat-
ment rate regularly increased from 1.1 % in 2000 to
4.2 % in 2012. However, since the proportion of naïve
patients regularly declined over time, while the propor-
tion of patients having failed a previous treatment in-
creased during the period, the incidence of retreatment
among failing patients was every year except 2008
greater than the incidence of first treatment in naïve pa-
tients (Fig. 1b). Therefore, treatment incidence in naïve
patients dropped to 4.6 % in 2011 and increased to 6.8 %
in 2012, while retreatment rate in failing patients dropped
to 6.7 % in 2010 and increased to 11.1 % in 2012.
Figure 2 shows the evolution of HCV treatment status
over time. Among all patients, the proportion of HCV
treatment naïve patients decreased from 80.8 % in 2000
to 40.7 % in 2012. When excluding patients with HCV
reinfection and patients who spontaneously cured their
HCV infection, the cumulative treatment initiation rate
increased from 14.8 % in 2000 to 54.7 % in 2012. During
the same period, the proportion of patients with SVR
Fig. 1 Incidence of HCV treatment initiations between 2000 and 2012. All treatment initiations, Direct-acting antiviral agents (DAA)-based treatments,
first treatment initiation and retreatment initiation in all patients with a detectable HCV-RNA (Panel a); First treatment initiation among naïve patients
and re-treatment initiation among failing patients (Panel b)
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increased from 1.7 to 22.2 %. The cure rate increased
from 12.4 % in 2000 to 45.2 % in 2012.
Factors associated with HCV treatment initiation over time
Table 2 and Fig. 3 show the parameters associated with
HCV treatment initiation and their effect over time. Sev-
eral parameters were associated with a greater treatment
initiation rate throughout the period, without any time
effect, such as an age over 40 (Fig. 3a), male gender
(Fig. 3b), men having sex with men (MSM) as a risk fac-
tor for HIV infection (Fig. 3c), CD4 cell count ≥350/mm3
(Fig. 3h) and an HIV-RNA ≤200 copies/mL (Fig. 3i). Con-
versely, HCV genotype was not associated with a greater
treatment initiation rate when considering the whole
period, while treatment initiation rate was doubled for
genotype 1 by comparison with non-1 genotype in 2012
(13.6 vs 5.6 %; Fig. 3e). Treatment was initiated more
frequently in patients at CDC stage A-B than in pa-
tients at CDC stage C, but this difference tended to de-
cline over time (Fig. 3g). A similar trend was observed
for patients with higher stages of fibrosis, with a re-
bound in treatment initiation for F3-F4 patients in
2012 (Fig. 3f ). Finally, patients with HCV infection of
less than 1 year were treated similarly as patients with
older infection during the first years. However, treat-
ment initiation rate of recent infections significantly in-
creased from 2008 onwards (Fig. 3d).
Discussion
The Dat’AIDS cohort represents a collaboration between
major French HIV treatment centers scattered through-
out the country [23] and today includes data on more
than 34,000 patients. The present study indicates that
Fig. 2 Evolution of HCV treatment status between 2000 and 2012
Table 2 Factors potentially associated with HCV treatment
initiation over time




First treatment vs retreatment <0.001 <0.001
Age (≤ vs > 40 years) 0.001 0.210
Gender <0.001 0.522
HIV risk factors (homosexual
vs other)
<0.001 0.519
HCV duration (< vs≥ 1 year <0.001 <0.001
HCV genotype (1 vs non-1) 0.190 <0.001
Liver fibrosis (F0-F2 vs F3-F4) <0.001 <0.001
CDC stage (A-B vs C) <0.001 <0.001
CD4 cell count (< vs≥ 350) <0.001 0.318
HIV RNA (≤ vs >200 copies/mL) <0.001 0.758
*The p-value associated with the group effect indicated whether the probability
of HCV treatment initiation differed between different groups. The p-value associated
with the interaction effect indicated whether different evolution of HCV treatment
initiation existed according to the groups. For example, the probability of HCV
treatment initiation is significantly higher among patients with liver fibrosis F3-F4
(p < 0.001) and evolution over time differed between those F0-F2 and
F3-F4 (p < 0.001)
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HCV prevalence among HIV-infected patients decreased
over the past decade, probably due to a decreased pro-
portion of IVDU among newly infected HIV individuals.
Since HCV coinfection is more frequent among IVDU
than among MSM, the increased proportion of MSM
and non-IVDU women among the HIV population over
time results in a parallel decrease of HCV prevalence
despite the occurrence of acute HCV infections in a
sub-population of MSM in the last years. Similar trends
have been described in other European and US cohorts
[4, 28, 29].
A significant improvement in HIV care was observed
during the study, as measured by the proportion of pa-
tients with an undetectable HIV-RNA under cART. This
improvement both reflects a better cART uptake in this
population and a better virological control of HIV infec-
tion and results in a significant improvement of the im-
munological status of the population. Both trends were
expected, since transversal analysis of several consecutive
cohorts from 2004 to 2012 showed similar patterns [4].
Fibrosis evaluation increased over time, notably after
2004, when non-invasive fibrosis evaluation techniques
became widely available. Following the introduction of
these techniques, they not only nearly replaced liver
biopsy, but the number of patients evaluated every year
more than doubled from 2000 to 2012. Variations in the
proportion of patients with severe fibrosis or cirrhosis
were observed over time. Whether these variations re-
sulted from the inclusion in the cohort of patients with
more recent infection when using non-invasive tech-
niques, or to other factors could not be determined.
Interestingly, fibrosis assessment was more frequent
among patients with previous virological failure. Since fi-
brosis score is associated with the probability of compli-
cation of chronic hepatitis C and with the probability of
response to Peg-Interferon/ribavirin, one can hypothesize
that physicians were more willing to precisely quantify the
risk/benefit ratio in these patients before considering an-
other treatment course.
Until 2002, there was not in France any specific rec-
ommendation for HCV treatment in HIV-HCV patients
[30]. In 2002, treatment was recommended if the
METAVIR score was ≥ F2 or ≥A2/A3 with a CD4 cell
count >200 cells/mm3 [31]. In 2006, recommendations
were extended to patients ≥ F2, ≥A2/A3, genotype 2 or 3
whatever the fibrosis score and to genotype 1 patients
with HCV RNA <800,000 IU/mL [32]. In 2008, treat-
ment of acute HCV infection was also recommended
Fig. 3 Parameters potentially associated with HCV treatment initiation over time: Age (panel a), gender (b), HIV risk factor (c), HCV duration (d),
HCV genotype (e), liver fibrosis (f), CDC stage (g), CD4 cell count (h), HIV-RNA (i)
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[33]. Fist-generation DAA, telaprevir and boceprevir be-
came available in April and July 2011, respectively, for
the treatment of patients with METAVIR F4 who had
previously failed a PEG-IFN therapy. Our study allowed
us to precisely describe the evolution of HCV treatment
initiation rate (Fig. 1). A particularly high proportion of
treated patients of 54.7 % was observed, resulting in a
cure rate of 45.2 % of the treated patients. Previous stud-
ies have reported lower treatment uptake in HIV/HCV
coinfected patients in various countries, including a re-
cent study within the Swiss HIV cohort, a cohort with a
similar number of patients [15]. Differences in the study
populations, differences between Health Care Systems
and the time at which these studies were conducted may
explain part of this difference. However, treatment up-
take appears notably higher in cohorts of HIV/HCV
coinfected patients than in HCV monoinfected patients.
A recent systematic survey in European countries re-
ported treatment uptake as low as 3.5 to 15 % in IVDU
[34] while treatment uptake of 10 to 23 % was reported
from a review of studies among US veterans, mainly
HCV monoinfected [35]. Whether these differences were
related to a better follow-up of coinfected patients under
antiretroviral treatment, or to the effect of wider recom-
mendations of treatment for HCV in coinfected patients
[21, 22] could not be asserted in this study.
Still, our data indicate that in 2012, 40.7 % of coin-
fected patients remained untreated for HCV, among
whom 27.5 % had either cirrhosis or severe fibrosis and
may require a priority access to treatment.
A decrease in all treatment initiations was observed
between 2007 and 2011 possibly explained by physicians
and patients choosing to wait for more potent and better
tolerated oral anti-HCV regimens rather than initiating
PEG-IFN/ribavirin therapy. A similar decrease was ob-
served during the same period in the EuroSIDA cohort
[12]. This decrease was followed by an increase due to
the arrival of the first-generation protease inhibitors (PI)
telaprevir and boceprevir which accounted for 29.1 % of
our treatment initiations in 2012. A similar increase was
reported in US veterans, following the approval of these
drugs in the US [35].
Our results finally clearly show that treatment initi-
ation is associated with a variety of host and viral factors
and that the influence of these parameters could change
over time. Among them, older age, male gender, con-
trolled HIV infection, improved CD4 cell count , and
non-C CDC stage are classically associated with more
frequent treatment initiation [12–15, 17, 18]. Interest-
ingly, treatment initiation rate in patients with HCV dur-
ation below 1 year doubled from 2007 to 2010 reflecting
the emergence of acute HCV infection at that time
[36, 37] and the perceived benefit of an early treatment
[38, 39]. In 2000, the proportion of F3-F4 patients
initiating HCV therapy was almost twice that of F0-F2
patients but this difference regularly decreased until
2011, probably because of the evolution of recommen-
dations of treating HIV/HCV coinfected patients regard-
less of the fibrosis stage [40]. In 2012, the proportion of
F3-F4 patients initiating therapy increased again probably
because of availability of first-generation PI being initially
recommended in pre-cirrhotic or cirrhotic patients. Since
these molecules were effective on genotype 1 only, the
proportion of genotype 1 patients initiating treatment
drastically increased from 2011 onwards.
Our study presents several limitations. Data were ob-
tained from a database mainly used in infectious diseases
units. Since care for HCV infection can be shared be-
tween infectious diseases units and hepatology units,
some data obtained in hepatology units could be miss-
ing, simply because the results were not entered in the
database. This would be particularly accurate for HCV
genotype and fibrosis evaluation. Thus, the data pre-
sented in this study may represent minimal estimates of
the true numbers. The study was also not designed to
precisely analyze the cause of death. Precise data regard-
ing cirrhosis decompensation were not obtained, and the
liver-related mortality reported in the study should also
be considered as a minimal estimate rather than a defin-
ite rate. However, regular quality control in local and ag-
gregated databases, including completeness analyzes for
key data and automated processes within the database to
obtain the virological response following HCV treatment
all concurred to ensure good quality.
Some authors recently showed that low treatment up-
take for HCV resulted from a combination of barriers at
the system, practitioner, and patient levels [11]. The au-
thors suggested several strategies to enhance HCV treat-
ment uptake in coinfected patients e.g. increasing the
number of providers offering HCV treatment, lowering
treatment costs, or providing enhanced HCV education
and training programs for practitioners working in the
field of HIV or addiction.
Conclusion
Our study indicates that significant improvements in
HIV care, fibrosis evaluation and HCV treatment initi-
ation were already attained among HIV/HCV coinfected
patients in France at the beginning of DAAs era, result-
ing in a previously unseen high treatment uptake. When
entering the better tolerated and highly efficacious all
oral DAAs combinations era [20], it will be interesting
to investigate forthcoming treatment uptake in this
population. However, it should be borne in mind that
reasonable treatment costs and enlarged treatment indi-
cations will probably be necessary to achieve higher rates
of treatment uptake. Given the very high efficacy of new
DAA-based regimens and if treatment initiation rate
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keeps increasing, HCV prevalence among HIV patients
will drastically decrease during the forthcoming years.
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